Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 29 Oct 2015
At a glance
- Drugs Afatinib (Primary) ; Nintedanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 29 Oct 2015 Results published in the British Journal of Cancer
- 06 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 May 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.